Land available for development

Illustrative plan of Phase 2 expansion land with indicative building layout.

Phase 2 plans

Ideas, new treatments and devices are being developed at Cambridge Biomedical Campus to meet the demands of the world’s healthcare challenges.

We succeed because of the strength of our ecosystem which allows ideas to develop and flourish. We have the physical space to accommodate new and expanding companies and the international connections to be the global hub for content and research. Having nurtured companies, developed a highly skilled workforce and encouraged outside investment in Cambridge, the Campus is ready to create and welcome the next generation of companies. A multi occupancy building of 160,000 sq ft can be accommodated, or alternatively a single occupancy building up to 400,000 sq ft. To discuss the development opportunities in Phase 2 of the Cambridge Biomedical Campus, please contact one of our agents at the bottom of the page.

6 reasons to locate to CBC.

In 2009, planning permission covering 70 acres became the catalyst for the first phase expansion of the campus, raising its status into a truly internationally competing academic health science centre.

The ensuing six years has seen new committed development hit 1,800,000 sq ft gross (167,224 sq m).

With the Phase 1 expansion land now fully committed, the Development of the Phase 2 expansion land is now underway. With a landscape-led approach, this next stage will thread a series of new high specification office and laboratory buildings between a string of green, shared spaces to promote formal and informal meetings.

The total Phase 2 floor area available for development is 807,000 sq ft (75,000 sq m) gross, comprising 636,000 sq ft (59,000 sq m) of commercial floor space, including Abcam, and 171,000 sf ft gross (15,900 sq m) of clinical floor space.

Anchoring the Phase 2 expansion land is the Abcam headquarters, a new 100,000 sq ft net (9290 sq m) Grade A office and laboratory building, built to suit their business needs.

The developers of the Phase 1 and Phase 2 expansion of the Cambridge Biomedical Campus are Liberty Property Trust and Countryside Properties.

Countryside Properties PLC

Countryside is a leading UK developer specialising in place making and urban regeneration with experience in delivering commercial development across the full range of market sectors which complement its highly successful residential and mixeduse schemes. Countryside’s main emphasis is on developing commercial space allied to its new communities or regeneration opportunities, such as the adjoining Great Kneighton development. Founded in 1958, Countryside is listed on the London Stock Exchange and operates across London, the South East and the North West of England. For the year ended 30 September 2017, Countryside had revenues of £1.029 billion.

Liberty Property Trust

Liberty Property Trust UK Limited is part of the Prologis group of companies (NYSE:PLD). Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of September 30, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 976 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment. Liberty’s involvement in the Biomedical Campus is directed by Andrew Blevins, the Liberty Property Trust UK Managing Director.